Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Keyphrases

• Phase II Trial 100%
• Neoadjuvant 100%
• Resectable Lung Cancer 100%
• Atezolizumab 100%
• Peripheral Blood 60%
• Immune Parameters 40%
• Confidence Interval 20%
• Tumor 20%
• Adverse Events 20%
• Monotherapy 20%
• Survival Rate 20%
• Pathological Response 20%
• Two-dose 20%
• Large Cohort 20%
• Phase II Study 20%
• New Therapeutic Approaches 20%
• Malignant Cells 20%
• Non-small Cell Lung Cancer (NSCLC) 20%
• Innate Immune Cells 20%
• Tumor Microenvironment 20%
• Patient Selection 20%
• Point Analysis 20%
• 3-year Survival 20%
• Immunophenotyping 20%
• Non-randomized Trial 20%
• Immune Toxicity 20%
• Safety Signal 20%
• Procedural Pain 20%
• Major Pathological Response 20%

Medicine and Dentistry

• Arm 100%
• Non Small Cell Lung Cancer 100%
• Phase II Trials 100%
• Atezolizumab 100%
• Immunocompetent Cell 75%
• Neoplasm 25%
• Adverse Event 25%
• Monotherapy 25%
• Survival Rate 25%
• Epidermal Growth Factor Receptor 25%
• Tumor Microenvironment 25%
• Patient Selection 25%
• Immunophenotyping 25%
• Procedural Pain 25%

Immunology and Microbiology

• Arm 100%
• Atezolizumab 100%
• Immunocompetent Cell 50%
• Survival Rate 25%
• Innate Immune Cell 25%